GENZYME CORPORATION

Taxation/Internal Revenue Code

Implementation of P.L. 111-148, Patient Protection & Affordable Health Care Act Excise Tax for Drugs and Biologics Extension of R& D Tax Credit Orphan Drug Tax CreditImplementation of American Taxpayer Relief Act of 2012 Tax Reform

TargetedSENATE · HOUSE OF REPRESENTATIVES · Health & Human Services, Dept of (HHS) · Agency for Healthcare Research & Quality (AHRQ) · Centers For Medicare and Medicaid Services (CMS)

Health Issues

Implementation of P.L. 111-148, Patient Protection & Affordable Health Care Act 340B Issues Drug Shortage Issues AHRQ Studies of Orphan DrugsDrug Supply Chain Security: H.R. 1919, Safeguarding Americas Pharmaceuticals Act of 2013 and S. 959, Pharmaceutical Compounding Quality and Accountability Act H.R. 1281, Newborn Screening Saves Lives Reauthorization Act of 2013

TargetedSENATE · HOUSE OF REPRESENTATIVES · Health & Human Services, Dept of (HHS) · Agency for Healthcare Research & Quality (AHRQ) · Centers For Medicare and Medicaid Services (CMS)

Medicare/Medicaid

ESRD "Bundling Issues" and ESRD Drug Reimbursement Issues HCPCS Coding Decisions Implementation of P.L. 111-148, Patient Protection & Affordable Health Care Act Least Costly Alternative PolicyChanges re: Medicare Part B and Average Sales Price Medicare Secondary Payor for ESRD Services Extension of Rebates on Medicare Part D Drugs Performance Measures for Bone and Mineral Metabolism for ESRD Program 340B Issues Implementation of American Taxpayer Relief Act of 2012 H.R. 413, to eliminate two-year delay including oral-only ESRD-related drugs in the Medicate ESRD prospective payment system S. 77, Prescription Drug and Health Improvement Act of 2013 S. 117, Medicare Prescription Drug Price Negotiation Act of 2013 H.R. 800, to exclude prompt pay discounts from the average sales price for drugs and biologics under Medicare Part B H.R. 1516, Cancer Patient Protection Act of 2013